Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Truist Securities analyst Richard Newitter reiterates Carlsmed (NASDAQ:CARL) with a Buy and raises the price target from $18...
BTIG analyst Ryan Zimmerman maintains Carlsmed (NASDAQ:CARL) with a Buy and raises the price target from $21 to $24.
Carlsmed (NASDAQ:CARL) raises FY2025 sales outlook from $45.500 million-$47.500 million to $49.000 million-$50.000 million vs $...
Carlsmed (NASDAQ:CARL) reported quarterly losses of $(0.40) per share which met the analyst consensus estimate. This is a 80.58...
